


Alnylam Pharmaceuticals

Focused on Developing RNAi Therapeutics

Alnylam is a biopharmaceutical company leading the development of RNA interference (RNAi) therapeutics. The discovery of RNAi has been heralded as a major scientific breakthrough, and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today.

RNAi is a natural mechanism of gene silencing that occurs in organisms ranging from plants to mammals. RNAi therapeutics in development have the potential to treat diverse disease states and help patients in a fundamentally new way.



Investigational RNAi Therapeutics

Active Product Pipeline and Experience to Date

RNAi therapeutics in development by Alnylam are engineered to enable a consistent level of target knockdown. Alnylam's pipeline of investigational RNAi therapeutics is currently focused in four Strategic Therapeutic Areas (STArS): **Genetic Medicines, Cardio-Metabolic Diseases, Infectious Disease, and CNS/Ocular Diseases** - and we are actively exploring other disease areas.



* As of April 2025 across all active programs. Numbers are approximate as many studies are ongoing and several are blinded.

To learn more about Alnylam and our pipeline advancements, please visit Alnylam.com

Our Pipeline

| PRODUCT | DISEASE | PIPELINE | | | |
|-------------------------------|--|----------|---------|---------|------------|
| | | PHASE 1 | PHASE 2 | PHASE 3 | COMMERCIAL |
| TTR | | | | | |
| ONPATTRO® (patisiran) | hATTR Amyloidosis with Polyneuropathy | | | | |
| AMVUTTRA® (vutrisiran) | ATTR Amyloidosis with Cardiomyopathy and hATTR Amyloidosis with Polyneuropathy | | | | |
| Nucresiran (ALN-TTRsc04) | ATTR Amyloidosis with Cardiomyopathy | | | | |
| RARE | | | | | |
| GIVLAARI® (givosiran) | Acute Hepatic Porphyria (AHP) | | | | |
| OXLUMO® (lumasiran) | Primary Hyperoxaluria Type 1 (PH1) | | | | |
| Qfitlia™ (fitusiran) | Hemophilia A or B¹ | | | | |
| Cemdisiran (+/- Pozelimab) | Myasthenia Gravis¹ | | | | |
| Cemdisiran (+ Pozelimab) | Paroxysmal Nocturnal Hemoglobinuria¹ | | | | |
| ALN-6400 | Bleeding Disorders | | | | |
| AG-236 (ALN-TMP) | Polycythemia Vera¹ | | | | |
| CARDIOVASCULAR | | | | | |
| Leqvio® (inclisiran) | Hypercholesterolemia¹ | | | | |
| Zilebesiran | Hypertension² | | | | |
| Zilebesiran + REVERSIR | Hypertension² | | | | |
| METABOLIC | | | | | |
| Rapirosiran (ALN-HSD) | Metabolic Dysfunction-Associated Steatohepatitis (MASH)¹ | | | | |
| ALN-4324 | Type 2 Diabetes Mellitus | | | | |
| ALN-PNP | Non-Alcoholic Fatty Liver Disease (NAFLD)³ | | | | |
| ALN-APOC3 | Dyslipidemia¹ | | | | |
| ALN-CIDEB | Metabolic Dysfunction-Associated Steatohepatitis (MASH)¹ | | | | |
| NEUROLOGIC | | | | | |
| Mivelsiran (ALN-APP) | Cerebral Amyloid Angiopathy (CAA)⁴ | | | | |
| Mivelsiran (ALN-APP) | Alzheimer's Disease ⁴ | | | | |
| ALN-HTT02 | Huntington's Disease⁵ | | | | |
| ALN-SOD | SOD1 Amyotrophic Lateral Sclerosis (ALS)³ | | | | |
| OTHER | | | | | |
| Cemdisiran (+/- Pozelimab) | Geographic Atrophy¹ | | | | |
| Elebsiran (+Tobevibart) | Hepatitis D Virus Infection¹ | | | | |
| ALN-BCAT | Hepatocellular Carcinoma | | | | |
| ALN-ANG3 | Healthy Volunteers¹ | | | | |
| ALN-F1202 | Healthy Volunteers¹ | | | | |

¹ Out-licensed with milestones and/or royalties

² Partnered, Alnylam-led development with US profit split and milestones/royalties ex-US

³ Partner-led with profit split

⁴ Product developed as part of a collaboration with Regeneron

⁵ Partnered, Alnylam-led with profit split

Alnylam Clinical Development Pipeline as of July 2025